A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS BALANCE, METABOLISM AND EXCRETION OF [14C]-PF-07304814 IN HEALTHY PARTICIPANTS USING A 14C-MICROTRACER APPROACH
Latest Information Update: 29 Dec 2021
Price :
$35 *
At a glance
- Drugs Lufotrelvir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 22 Dec 2021 Status changed from recruiting to completed.
- 15 Dec 2021 Planned End Date changed from 17 Dec 2021 to 10 Dec 2021.
- 15 Dec 2021 Planned primary completion date changed from 17 Dec 2021 to 10 Dec 2021.